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found to undergo a rapid shift of their g pe to the
pure mutant type. The other 8 cell lines, which 6
exhibiting nearly homoplasmic mutant mtDNA, on the con-
ary, main a stable genotype. Subeoning
and growth rate _ tseady
ar epcative advte of mutant tDNA was maGliy
resnible for the dramAk sift toward themutgantpe
observed in the untable cell lines.
The rules that govern selection, segregation, and comple-
mentation of different mtDNA molecules at the intracellular
and cell population levels are poorly understood. In mam-
malian cells, until recently, the available evidence was lim-
ited to the behavior of drug-resistance-inducing mutations in
cell hybrids and cybrids (cells fused to cytoplasts), and
pointed to a random drift to the mutant or wild-type genotype
in the absence of selection (1) and to a propagative advantage
of the resistance-conferring mutant mtDNA in the presence
of the drug (1, 2). The recent identification of human disor-
ders associated with mtDNA mutations (3) has provided an
opportunity for investigating the transmission of natural
mutations in the patient's cells in vivo or in their in vitro
derivatives. Thus, an accumulation of deleted mtDNA mol-
ecules relative to coexisting wild-type genomes has been
reported in skeletal muscle fibers of patients with mitochon-
drial diseases (4, 5) and in cybrids derived from patient's cells
(6).
In the present work, cell lines containing in heteroplasmic
form the mitochondrial tRNAI-u(uuR) gene mutation associ-
ated with the MELAS syndrome (mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like episodes)
(7-9) that were constructed by introducing patient mitochon-
dria into human mtDNA-less (p0) cells (10) were used to
investigate the behavior of mutant and wild-type mtDNAs
upon prolonged subculturing. The MELAS mutation has
been shown (11, 12) to cause serious defects in mitochondrial
protein synthesis and respiration in cell lines carrying it in
homoplasmic form. The heteroplasmic transformants ana-
lyzed in the present work exhibited either an unstable or a
stable genotype. Surprisingly, in all unstable heteroplasmic
transformants, a dramatic shift toward the pure mutant
genotype was observed. The rapidity of the shift and growth
rate measurements clearly pointed to a marked replicative
advantage of the mutant mtDNA as being mainly responsible
for the phenomenon observed here.
MATERIALS AND METHOS
Myobast Cultures and Mltochodrla.Meae p046 Cell
TV.n~brnu~lon- Mass myoblast cultures were established
from muscle biopsy specimens by using reported procedures
(13-15). Conditions ofgrowth of the p026 cell line and p0206
cell transformation by cytoplast fusion were as described
(16). Transformants were grown in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% (vol/vol)
dialyzed fetal calf serum and bromodeoxyuridine at 100
Ag/ml. The population doubling time of the transformants
was determined from growth curves or by using the formula:
DT = (t - to)log 2/(log N - log NO),
whereDTis doubling time, t and to are the times at which cells
were counted, N and No are cell numbers at times t and to,
respectively. Subcloning was carried out by mixing samples
of =20 cells from each transformant with 105 p206 cells in
DMEM with 10%o fetal calf serum and bromodeoxyuridine at
100 pg/ml and plating them in a 96-well plate at a final cell
density of 0.2 transformant plus 103 p0 cells per well. Plating
efficiency varied between 16% and 10%.
DNA Anaiysis. The presence and proportion of mutated
mtDNA in total DNA samples (prepared by using a Applied
Biosystems 340A extractor or by proteinase K: digestion of a
0.5% Tween 20 cell lysate) were determed y testing for the
presence of the Apa I site created by the IMLAS mutation
at position 3243 (7-9) in a fragment amplfied by aPCR using
oligonucleotides corresponding to positions 3031-3050 and
3341-3360. The proportion of digested and undigested mol-
ecules was determined by laser densitometry after ethidium
bromide staining of the agarose gel. To correct for possible
resistance to digestion of heteroduplexes of wild-type and
mutant mtDNA formed during the final stages of PCR am-
plification (17), a mixed-template standard curve was con-
structed by PCR amplification of a mtDNA fiagment con-
taining the mutation from total DNA samples of 43B cells,
containing 99% mutated mtDNA, and transformant 94C,
containing exclusively wild-type mtDNA (12). Different ratio
mixtures of the mutant and wild-type PCR products were
then used for a second cycle of PCR amplification. Fig. 1
compares the mixed template standard curve (curve T) thus
constructed with the mixed product standard curve (curve P),
obtained by mixing the PCR products independently ampli-
fied from 43B-derived and 94C-derived PCR products in
different ratios and then subjecting the mixtures to Apa I
digestion.
Abbreviation: MELAS, mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes.
11164
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 89 (1992) 11165
T
0.
-50 -
50 100
% WT in mtDNA
FiG. 1. Construction of standard curves for the quantitai of
the MELAS mutation in mtDNA. Curves: T, mixed-template stan-
dard curve; P, mixed-product standard curve. WT, wild type.
Slot blot analysis of total DNA samples for quantitation of
mtDNA was carried out as described (10) usi the mtDNA
clone pTZ18/K4 (containing a fiagment from positions 41 to
2578), 32P-Iabeled by random prming (18), as a probe. The
data were normalized relative to hybridization to a nuclear
28S rRNA probe, constructed by PCR amplification from the
28S rRNA gene (19).
RESULTS
Transfer of Mltohoira from Myoblauts ofMMu-
tattonCarrylnglnullvlqlumk top Cels. Some ofthe mitochon-
drial transformants investigated here were derived from
myoblast cultures of MELAS patient 43, his asymptomatic
matenally related aunt (patient 94), and a second MELAS
patient, 2S, as described (12). Other transformants were
produced from myoblast cultures ofthree additionalMELAS
patients. Of these, two (patients 3E and 4H) were brothers of
Afro-American lineage, 8 and 13 years old, respectively, and
the third (patient SX) was an isolated 11.5-year-old female
Caucasian who suffered from MELAS syndrome and epi-
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lepsy. These three patients exhibited the MELAS 3243
mutation in heteroplasm form in the skeletal muscle, uri-
nary epithelial cells, and periphenl blood cells.
The majority of, nsformants obtainedm the myoblast
cultures ofpatients 3E and4H (which _ d68% wad 82%
mutant mtDNA, respectively) exhibited -;sfonly predomi-
nant mutant mtDNA, a few were or nearly
homoplasmic for wild-type mtDNA, and Go <3E7) exhibited
an intermediate genotype. By contrast, of 1) tranforrmant
clones produced from the myoblast cultue ofpatient 5X
(which contained 35% mutant mtDNA) hed pure or
virtually pure wild-type mtDNA and one clone (5X1) had an
intermediate genotype.
err Met" amd WiTy in MELAS
lrbm~rmb. In the courseofcoin t ring, it was
unexpectedly observed that the mitochandial genotype in
one ofthe relative 94-derived trasomant -94B, underwent
a marked change. As shown in Fig. 2 A Upper and D, the
original culture 94B exhibited a d decrease in its
wild-type mtDNA content, which dropped-f S% to 11%
in 33 days, and then a slower decrease to 4.5%i over the next
36 days. A culture derived from another vil ofearly94B cells
(948') exhibited the identical behavior (Fig. 2 A Lower and
D). In contrast, another 94 transformant(94) that initially
contained 71% wild-type mtDNA m d this level un-
changed (71-74%) for 6 weeks (Fig. 23 audP). Two other 94
transformants (94I and 94L) exhibited appeny pure wild-
type mtDNA for 4-5 weeks (Fig. 2D). Fig. 20 shows the
behavior ofthe 43B transformant, whichm tined a t
mtl)NA content of 97-99% for 7 weeks. Asi bevior
was observed in another 43 transforma (4 and a 94
transformant (94A), which contained strongly predominant
mutant mtDNA (data not shown).
As shown in Fig. 2D, an 02 ConsOUptinof 4.5 fmol per
min per cell, which is within the nor e found for
several 94 transformants containing1 - mtDNA
(12), was measured when the wild-type content of
94B was 11%. The 02 consumption to 2.1 fimo per
min per cell when the wild-type mtDNA c hot become
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FiG. 2. mtDNA carrying the MELAS mutation rapidly replaces the predominant wild-type mtDNA or remains constant during growth of
diffeent heteroplasmic MELAS transfomants. (A-C Genotype aaysis of trnunsfnsa 943 (A Uper), 94B', derived ft. anohe vial of
ealy 94B cells (A Lower), 94H, isolated fimm the asymp individual 94 (0), and 2SE, isled from ELAS petet 2S (C), and of
143B.TK cells (C). Iin.KS, plluescript KS+ DNA, linearized with Xmn I, added as internal unter for co -ofion 11 Hae
III-digeted pBluescript KS+ DNA. (D) Quantitative behvior of wid-type wM A during rowth ofMLAS 93, 94H, 43R,
and 2SE and 02 consumption in trandomant94B. The dotted portiasofthe curves reprsent interruptions ingrow*th to _adtN W la.
ofcells.02 consumption was measured as described (10). (E)Qutitative behavior ofwild-typemtDNA durin growth*fMELASiansnorMaas
3E1, 3E7, 4H1, 4H6, and 5X1. WT, wild type.
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9%o and remained around 2.3-2.5 fmol per min per cell over
the next 17 days, as the wild-type mtDNA content declined
to 6%. Previously, a striking protective effect of wild-type
mtDNA against the phenotypic manifestation ofthe MELAS
mutation, with a sharp transition around an average wild-type
mtDNA proportion of 6%6 and with full protection by l1O%
wild-type mtDNA, has been observed (12). The present
observations for 94B, therefore, fit in well with the above
data. The finding that, in the 94B heteroplasmic transform-
ant, the mtDNA shift to mutant type went beyond the
threshold protective level of wild-type mtDNA, causing a
defect in the respiratory capacity of the transformant to
appear, indicates that this defect did not produce a significant
growth disadvantage in the affected cells, probably due to an
adaptation that allows the cells to rely on glycolysis for their
energy requirements. The growth rate measurements dis-
cussed below support this conclusion.
To investigate whether the unusual behavior ofthe mtDNA
in the 94 transformants was related to some property of its
sequence, genotypes of heteroplasmic transformants derived
from other genetically unrelated MELAS patients were an-
alyzed. As shown in Fig. 2 C, D, and E, transformants 2SE,
3E7, and 5X1 (derived from patients 2S, 3E, and 5X, respec-
tively) exhibited the same dramatic decrease of wild-type
mtDNA observed in the 94B transformant. In particular, in
transformant 2SE, the wild-type genomes decreased from
90%o after thawing to 50% after 19 days in culture and to 9%
after an additional 7 days (Fig. 2 C and D). In two other clones
(3E1 and 4H1), the proportion of wild-type mtDNA was
initially 15% and 6%, respectively, then declined to 2-3% in
7-8 days, and remained at this level over the next 4 weeks
(Fig. 2E). It seems very likely that the 3E1 clone, at the time
of its first analysis, was in the final stage of a rapid genotype
shift toward pure mutant type. Finally, other transformant
clones maintained their initial nearly homoplasmic (>95%)
wild-type genotype [4H6 (Fig. 2E)] or nearly homoplasmic
mutant genotype (2SC and 2SD) over 3-5 weeks (data not
shown). In summary, in the present work, of 23 heteroplas-
mic transformants found among 48 clones derived from
individuals belonging to four pedigrees with the MELAS
mutation, the mtDNAs of 13 transformants were analyzed
over a prolonged period and shown to undergo a rapid shift
to the mutant genotype or to maintain a stable genotype. In
no case was a shift toward the wild-type mtDNA genome
observed. The remnng 10 heteroplasmic clones, containing
nearly pure mutant mtDNA, were not analyzed further.
Subdoning of MELAS Transfornants. To obtain some
insight into the mechanism of the rapid genotype shift of the
unstable heteroplasmic transformants described above and
the basis for the behavior of the 94H and 4H6 transformants,
cultures of 94B, 2SE, and 94H were subjected to one or two
steps of subcloning at different times after their isolation.
Among 17 subclones derived from the 94B transformant
when its genotype exhibited >90% wild-type mtDNA, 9
subclones showed an apparently homoplasmic wild-type
genotype, 1 (subclone 10) exhibited almost pure (--99o%)
wild-type mtDNA, and 7 contained predominantly (>81%)
mutant mtDNA presumably as a result of a shift in genotype
(Fig. 3 A Upper and B). Second-step subcloning of clone 10
produced 10 clones, of which 8 maintained a nearly ho-
moplasmic wild-type mtDNA for 18 days and the other 2
exhibited the beginning ofa shift to mutant mtDNA (Fig. 3B).
The poor growth ofthe last two clones prevented their further
analysis.
In a second 94B subcloning experiment, carried out when
the genotype showed 58% wild-type mtDNA, among 10
subclones, 5 subclones still exhibited apparently homoplas-
mic wild-type mtDNA and 5 contained heteroplasmic
mtDNA, with a level of wild-type mtDNA between 8% and
22%. Upon further culturing, the 5 heteroplasmic subclones
exhibited a progressive decrease of wild-type mtDNA, to
3.5-7.5% 3 weeks after subcloning (Fig. 3C Upper). All five
apparently homoplasmic wild-type clones exhibited 100%
wild-type mtDNA at the earliest analyzed time point (10 days
after subcloning), without any evidence of transitional geno-
type, as opposed to the gradually changing genotype of the
subclones shifting to the mutant type. This observation
strongly argues that these apparently homoplasmic wild-type
clones preexisted as such in the original 94B population.
Furthermore, the progressive decline in the poportion of
wild-type mtDNA in the 94B mother culture implies that a
continuous recruiting of clones shifting to the mutant geno-
type must have occurred from the pool of apparently ho-
moplasmic wild-type clones.
Quantitation of the mtDNA content in the mother culture
at the time of subcloning and in the 10 subclones (Fig. 3C
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FIo. 3. Genotype behavior of subclones of mitochondrial transformants derived from asymptomatic individual 94. (A) Genotype analysis
of some of the first-step subclones (1-17) of the 94B transformants and subclones (1-11) of94H tnformant. Arrows in B and D indicate times
of subcloning. Orig., sample of mother culture. (B and C) Quantitative behavior of wild-type mtDNA in subclones deriving from 94B 25 days
(B) and 34 days (C) after isolation of the transformant. The dotted line reproduces the curve of Fig. 2D illustrating the qaitive bhavior
of wild-type mtDNA in transformant 94B-94B'. Open symbols represent clones with apparently homoplasmic wild-type mtDNA. In C Upper,
the first point in the curve for subclones 1-5 pertains to all subclones (see text for details). (C Lower) Total mtDNA content in the first-step
subclones and the mother culture. (D) Quantitative behavior of wild-type mtDNA in subclones derived from 94H transformant. WT, wild type.
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Lower) showed that no significant change in the average
amount of mtDNA per cell had occurred between the isola-
tion of the subclones and 2.5 weeks later, when the propor-
tion of wild-type mtDNA in the heteroplasmic subclones had
decreased to one-half (Fig. 3C Upper). This observation
indicated that a decrease in the absolute average amount of
wild-type mtDNA per cell had taken place in these subclones
during the same period. Second-step subcloning of one of the
heteroplasmic clones with 4% wild-type mtDNA produced 5
subclones that exhibited limited genotype variability around
this value (Fig. 3C Upper).
Subcloning of the 2SE transformant -5 weeks and =9
weeks after its isolation gave results similar to those de-
scribed above for 94B (Fig. 4). For both transformants, the
subcloning experiments indicated that the cultures undergo-
ing a shift of their genotype to mutant mtDNA consisted of
cell populations that were very heterogeneous in their mutant
to wild-type mtDNA ratio and exhibited a progressive general
shift toward the mutant genotype, with the proportion of cells
containing homoplasmic or near homoplasmic wild-type
mtDNA decreasing progressively with the time in culture.
These results indicated that the shift toward the mutant type
started at different times and/or proceeded at different rates
in the individual cells of the unstable populations.
Subcloning of the 94H transformant carried out -9 weeks
after its isolation, when the genotype showed -73% wild-
type mtDNA, gave 11 subclones that, in contrast to 94B and
2SE, exhibited only limited variability (between 62% and
80%) in wild-type mtDNA content (Fig. 3 A Lower and D).
The Genotpe Shift Does Not Result from Intercellular Se-
lection Due to Differential Growth Rates. The rapidity of the
shift toward mutant mtDNA observed in the unstable cell lines
argued strongly against its being caused by cells with more
mutant mtDNA growing faster than those with less mutant
mtDNA. Evidence against intercellular selection was pro-
vided by a comparison ofthe doubling times ofmany MELAS
transformants exhibiting widely different proportions of mu-
tant mtDNA (Table 1). Small differences in doubling times
were observed among different clones, probably reflecting
variations in nuclear or mtDNA background, or in clone age.
However, for a given transformant clone, no significant con-
sistent difference in growth rate was found between stages or
subclones homoplasmic or nearly homoplasmic for wild-type
mtDNA or stages with 50-70%o wild-type mtDNA and stages
or subclones exhibiting nearly homoplasmic or strongly pre-
dominant mutant mtDNA. This is dramatically illustrated by
11
z
E
0O0
Table 1. Growth rates of MELAS transformants
Transformant % WT mtDNA Doubling time, hr
94B early* >90 31
94B earlyt 70 26
94B late* 10 -4.5 25
94B' 58 -19 24
94B' 19 8 24
94B-subclones 1-5§ 100 27-34
94B-subclones 6-10§ 4.5-6 25-31
94H 72 30
941 100 34
94L 100 35
43B 2-3 29
2SA 100 25
2SB 100 24
2SD 6 23
2SE 50 23
WT, wild type.
*At 24-28 days after fusion.
tAt 33 days after fusion, culture derived from a frozen stock.
tAt 63-97 days after fusion.
§Derived from subcloning of94B carried out 34 days after fusion (Fig.
3C).
the experiment shown in Fig. 5, where 94B' cells, kept in
continuous culture for 41 days, exhibited a decrease in the
proportion of wild-type mtDNA from 58% to 8%, while
maintaining an absolutely constant 24-hr doubling time. Fur-
thermore, even in the cases where a slightly longer doubling
time was estimated for cells with mostly wild-type mtDNA, as
compared to cells with mostly mutant mtDNA, the increase in
percent mutant mtDNA expected as a result of differential
growth rates would have been much less than the increase
actually observed. Thus, for 2SE cells grown continuously for
26 days, with an observed decrease of wild-type mtDNA from
90% to 9% (Fig. 2D), the decrease in proportion of wild-type
mtDNA expected from intercellular selection would have been
much less [i.e., from 90%o to 67%; as calculated conservatively
by using the values 25 hr (obtained for clone 2SA) and 23 hr
(obtained for clone 2SD) (Table 1) as doubling times for cells
containing a high percentage and a low percentage ofwild-type
mtDNA, respectively]. These quantitative considerations and
the direct observations shown in Fig. 5 are not compatible with
a significant role of intercellular selection in the phenomenon
investigated here and rather point to an intracellular process
involving a replicative advantage of the mutant mtDNA mol-
ecules.
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FIG. 4. Genotype behavior of subclones (as indicated) of mito-
chondrial transformant 2SE, derived from MELAS patient 2S. The
dotted line reproduces the curve of Fig. 2D illustrating the quanti-
tative behavior of wild-type mtDNA in transformant 2SE. WT, wild
type.
70
60 Z0
50 E()
0-
40 >
30 3-
20 c(D
u
Ca
0
Days after fusion
FIG. 5. Rapid genotype shift toward mutant mtDNA of the 94B'
transformant does not involve any change in growth rate. The figure
shows the growth curve (open symbols) and the genotype change
(solid symbols) during continuous subculturing of the 94B' clone.
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DISCUSSION
The central observation reported here (i.e., the preferential
replication of mtDNA molecules carrying the MELAS mu-
tation over wild-type molecules) extends the phenomenon of
"ssuppressiveness" to a higher eukaryote mtDNA with a
point mutation. Suppressiveness was originally described in
yeast for a subclass of "petite" mtDNA mutations (20) and,
subsequently, in Neurospora and other filamentous fungi for
senescence processes leading to the replacement of normal
mtDNA with grossly abnormal mtDNA (21-24). In the pres-
ent work, the evidence obtained excludes a significant role of
intercellular selection of faster growing mutant mtDNA-
enriched cells in the genotype shift observed in unstable
heteroplasmic MELAS transformants. The alternative pos-
sibility of an unequal segregation of mutant and wild-type
mtDNA into daughter cells at cell division, with the daughter
cells receiving more mutant mtDNA undergoing a compen-
satory nonselective mtDNA amplification, seems very un-
likely in the present mammalian cell system. In fact, it would
require a unidirectionality of unequal segregation events in
successive division cycles, for which no known mechanism
exists. Therefore, the most reasonable interpretation of the
present data is that a replicative advantage of mutant mtDNA
molecules over wild-type molecules is the main factor re-
sponsible for the observed genotype shift. This replicative
advantage may explain the observations made here and in
previous work (11, 12), indicating that the great majority of
the transformants obtained by transfer of mitochondria from
MELAS patient into p0 cells contained either homoplasmic or
near-homoplasmic wild-type mtDNA or strongly predomi-
nant mutant mtDNA, with very few transformants exhibiting
an intermediate genotype.
As to the mechanism of the phenomenon investigated here,
neither a smaller size of the mutant mtDNA molecules (25)
nor, presumably, the loss of cis-acting control elements (5),
factors that have been previously considered to explain the
accumulation of mtDNA molecules with large deletions in
mitochondrial -diseases, could play a role. A plausible mech-
anism is one involving a feedback phenomenon that induces
the selective replication of mtDNA in organelles functionally
compromised by the presence of mutated mtDNA. This
possibility has been raised before to account for the prefer-
ential accumulation of deleted or otherwise grossly altered
mtDNA (5, 24). However, any model-involving selection at
the level of individual organelles would have to explain the
present findings of two transformants (94H and 4H6) that did
not exhibit an amplification of the mutant DNA over 5-6
weeks. The observation reported here and elsewhere (12) that
the phenotypic manifestation of the MELAS mutation can be
complemented by a small minority (>6%) of wild-type ge-
nomes suggests that segregation of mutant molecules in pure
form in separate organelles (i.e., intermitochondrial hetero-
plasmy) may be the critical factor controlling the replicative
advantage of the defective mtDNA molecules. Transfor-
mants 94H and 4H6 may represent examples of a situation
where stable intermixing of mutant and wild-type mtDNA
molecules (intramitochondrial heteroplasmy) would allow a
complementation of the defect(s) caused by the mutation and
thus prevent the replicative advantage of defective mtDNA
molecules from being manifested. Another important ques-
tion is whether the replicative advantage of mutant mtDNA
molecules observed here is somehow linked to the particular
nature of the MELAS mutation or whether it reflects a more
general behavior of defective mtDNA.
It seems possible that the "crippled mitochondrion" model
for the replicative advantage of mutant mtDNA is also
applicable to the clonal expansion of the single deletion
events early in development that produces the accumulation
of deleted mtDNA molecules (26). Furthermore, it is reason-
able that the shift in genotype toward higher proportions of
mutant mtDNA, with increasing signs of mitochondrial dys-
function, observed in successive generations of Leber he-
reditary optic neuropathy pedigrees (27, 28) and ofaMELAS
pedigree (29), could reflect the operation in the oocytes ofthe
same mechanism for a replicative advantage of the mutant
mtDNA molecules.
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